The Protein Diagnostics Market encompasses a broad range of technologies and applications supporting clinical diagnosis, pharmaceutical research, and personalized healthcare. WiseGuyReports estimates that the market will increase from USD 8.9 billion in 2024 to USD 15 billion by 2035, with a projected CAGR of 4.9%.

By application, the market includes clinical diagnostics, drug discovery, personalized medicine, and research and development. Clinical diagnostics represents a major application because protein-based testing is widely used to identify and monitor disease-related biomarkers.

By technology, the market covers mass spectrometry, electrophoresis, immunoassays, Western blotting, and protein microarrays. Immunoassays are particularly important because of their sensitivity, versatility, and broad use across diagnostic applications.

The end-use segment includes hospitals, laboratories, pharmaceutical companies, and academic institutions. Pharmaceutical companies increasingly utilize protein diagnostics for drug discovery, biomarker identification, and therapeutic monitoring.

Key companies identified in the market include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories, QIAGEN, Beckman Coulter, Agilent Technologies, and MilliporeSigma.

Regionally, North America leads the market, while Europe maintains a significant position supported by healthcare investment and research activities. Asia-Pacific is expected to demonstrate strong growth as healthcare infrastructure and diagnostic adoption improve.

Competition is expected to remain focused on technological innovation, product development, strategic collaborations, and expansion of diagnostic capabilities.